A prospective, multi-center, single-arm study, planned in 150 patients. The primary objective of the study is to further evaluate the safety and efficacy of a magnetic resonance imaging (MRI)-guided transurethral ultrasound therapy system (TULSA-PRO) intended to ablate prostate tissue of patients with localized, organ-confined prostate cancer.
This trial phase represents an early or specialized stage of clinical development.
Enrollment is complete. The trial is in its follow-up or data collection phase — a readout may occur on or near the primary completion date.
Profound Medical (PRN) is the sponsoring company for this trial. BiotechSign currently grades this company D (46/100) based on composite catalyst signals across its full pipeline. This trial is one data point in that overall catalyst picture.